Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting <scp>PD</scp>‐1 and <scp>VEGF</scp>, in Chinese Patients With Advanced Solid Tumors

Authors

Yulong Zheng (ORCID: https://orcid.org/0000-0002-1401-9883)
Xufang Yu (ORCID: https://orcid.org/0009-0000-4623-3203)
Benchao Chen
Jing Wang (ORCID: https://orcid.org/0000-0002-9495-781X)
Lei Ma (ORCID: https://orcid.org/0009-0002-0386-5731)
Feng‐Hua Wang (ORCID: https://orcid.org/0000-0003-1016-6867)
Hui Luo (ORCID: https://orcid.org/0000-0001-6312-9299)
Rui‐Hua Xu (ORCID: https://orcid.org/0000-0001-9771-8534)
Xiaoli Wei (ORCID: https://orcid.org/0000-0001-8414-4957)
Xiaozhong Chen (ORCID: https://orcid.org/0000-0003-4351-9753)
Suxia Luo
Jieer Ying

Institutions

Sun Yat-sen University (CN)
Zhejiang Cancer Hospital (CN)
Hunan Cancer Hospital (CN)
Henan Cancer Hospital (CN)
Sun Yat-sen University Cancer Center (CN)
First Affiliated Hospital Zhejiang University (CN)

Publication Details

Journal: Cancer Medicine
Published: 2025-03-01
DOI: https://doi.org/10.1002/cam4.70653
Citations: 7
Primary Topic: Monoclonal and Polyclonal Antibodies Research
Type: article
Field-Weighted Citation Impact: 9.52

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD‐1 and VEGF, in Chinese Patients With Advanced Solid Tumors

Yulong Zheng, Xufang Yu, Benchao Chen, Jing Wang et al.

Mar 1, 2025

7 citations

Cancer Medicine

Monoclonal and Polyclonal Antibodies Research

9.52

article

Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD‐1 and VEGF, in Chinese Patients With Advanced Solid Tumors

Yulong Zheng, Xufang Yu, Benchao Chen, Jing Wang, Lei Ma, Feng‐Hua Wang, Hui Luo, Rui‐Hua Xu, Xiaoli Wei, Xiaozhong Chen, Suxia Luo, Jieer Ying

March 1, 2025article en

7 citations

Abstract

No abstract available for this paper.

Cancer MedicineVol. 14(6)

Sun Yat-sen University (CN), Zhejiang Cancer Hospital (CN), Hunan Cancer Hospital (CN), Henan Cancer Hospital (CN), Sun Yat-sen University Cancer Center (CN), First Affiliated Hospital Zhejiang University (CN)

Good health and well-being

Openalex Percentile: Top 2%

Monoclonal and Polyclonal Antibodies Research

9.52

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting <scp>PD</scp>‐1 and <scp>VEGF</scp>, in Chinese Patients With Advanced Solid Tumors — Yulong Zheng, Xufang Yu, et al. · Cancer Medicine (2025) | TGRS Research Map | TGRS